Treamid Therapeutics

Executive Summary

Treamid Therapeutics is a private, Phase 1-stage biopharmaceutical company based in Munich, Germany, founded in 2016. The company focuses on the development of small molecule therapies, though its specific therapeutic areas and lead programs are not publicly disclosed. Based on its name and early-stage profile, Treamid is likely developing novel treatments for neurodegenerative or movement disorders, such as tremors or ataxia. As a private company with no disclosed funding rounds or valuation, Treamid operates with limited visibility into its pipeline and financial health. The company maintains a general informational website without detailed product or clinical data, suggesting it may still be in preclinical or early clinical development, with potential Phase 1 data expected in the near term.

Upcoming Catalysts (preview)

• Q4 2026Initiation of First Phase 1 Clinical Trial30% success
• Q2 2026Presentation of Preclinical Data at a Major Medical Conference50% success
• Q3 2026Series A Financing Round Announcement25% success